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ED I T OR I A L
Giant cell arteritis, truly a form 
of systemic vasculitis
A. Rutgers1*, D.J. Mulder2, E. Brouwer1
Departments of 1Rheumatology & Clinical Immunology, 2Internal Medicine, University Medical 
Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands, 
*corresponding author: email: a.rutgers@umcg.nl
Giant cell arteritis (GCA) was first described as a temporal 
arteritis by Horton, Magath and Brown in 1932, but Cooke 
et al. already demonstrated in 1945 by autopsy that it 
could be a generalised vasculitis of the aorta and its main 
branches.1 In fact, Cooke recognised that in the elderly 
‘a widespread arterial disease existed, not uncommon 
but rarely recognised’. Moreover he stated that the term 
temporal arteritis has been retained to indicate a specific 
clinical entity in the absence of any definite aetiological 
factor. Nowadays, with the availability of modern age 
imaging (ultrasound, PET-CT, CTA, MRA,) the awareness 
of extracranial GCA has risen significantly. GCA is the 
most prevalent form of systemic vasculitis, especially in 
ageing Caucasian populations.2
Lensen et al. wrote an elaborate narrative review on 
extracranial GCA.3 It is apparent that a clear consensus 
on the best diagnostic imaging modality is lacking and 
that the diagnosis is usually based on the clinical signs 
and symptoms together with the locally available imaging 
modalities and expertise. Also, they point out that 
evidence-based treatment guidelines are lacking and that 
the same treatment regimen for cranial and non-cranial 
GCA is applied. Moreover, it is unclear what the best 
strategy is to monitor disease activity and how to deal with 
relapsing patients. The latter is a clear problem since up to 
64% of patients with GCA experience a relapse.4 Part of 
the lack of knowledge and/or consensus might be due to 
the high variability in presenting clinical symptoms, from 
headache to night sweats and polymyalgia rheumatica 
like symptoms, as well as the associated dispersion over 
many different medical specialists, including general 
practitioners, neurologists, ophthalmologists, internists, 
rheumatologists, and vascular surgeons. It is increasingly 
recognised that GCA is a debilitating disease, which 
causes significant morbidity in otherwise healthy 50+ 
persons, not in the least due to the long-term use of 
glucocorticoids. 
Improving outcome has to start with early and timely 
recognition of patients presenting with GCA. Especially 
cranial GCA symptoms are linked to irreversible loss of 
vision and this could be prevented by early aggressive 
treatment with steroids.5 Also, the recognition of aortic 
structural damage including aneurysm development is 
of importance. However, long-term incidence and the 
relative contribution of atherosclerotic and inflammatory 
components are unclear and better studies are needed. 
Fast-track clinical pathways have been established in 
several specialist centres, providing initial diagnostic 
evaluation and treatment of patients with suspected GCA 
within 24 hours. Preliminary results suggest a significant 
reduction of permanent visual impairment compared with 
conventional referral strategies.6
Another important issue that needs to be addressed is 
increasing public and general practitioner awareness of 
GCA as a debilitating disease in order to reduce the referral 
time to the fast track clinic.
Ideally a fixed work-up protocol with standardised and 
validated lab and imaging techniques should be available 
in a day-care setting. In such a setup, ultrasound is a 
promising tool, and not only for cranial GCA, as it is 
easily accessible and relatively inexpensive in contrast to 
more advanced imaging strategies. Since the landmark 
study by Schmidt in 1997,7 several studies on the use of 
Duplex ultrasound (combination of colour Doppler and 
pulsed-wave-Doppler) in the diagnosis and follow-up 
of cranial GCA have been published. In addition to 
early detection of stenosis and occlusion, a typical dark 
hypoechoic, circumferential wall thickening is usually 
observed in a vessel affected by vasculitis, referred 
to as the ‘halo’ sign. For cranial GCA, the accuracy 
has been tested in several studies, using histological 
diagnosis as the gold standard, yielding good sensitivity, 
specificity, and reproducibility when performed by 
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experienced sonographers. Preliminary results from the 
recently completed prospective multicentre TABUL study 
(Temporal Artery Biopsy vs Ultrasound in diagnosis of 
GCA; NCT00974883) including 415 cases with suspected 
cranial GCA suggests that ultrasound is only of diagnostic 
value if performed within four days of steroid initiation 
as the typical halo quickly diminished over time. Of 
importance, these typical ultrasound signs can also be 
observed in patients with extracranial GCA, predominantly 
affecting axillary, subclavian and/or proximal brachial 
arteries. Clinical cohorts have suggested that the axillary 
artery may be very useful and is generally found to be 
affected in most cases of extracranial GCA.8 However, 
contrary to temporal ultrasound, it is not possible to use 
histology as a gold standard and no formal validation study 
has been performed. 
Treatment should be started promptly in GCA patients 
with cranial symptoms, but can probably be delayed in 
extracranial GCA in order to make the proper diagnosis. 
Whether aggressive treatment also leads to a decrease in 
long-term aortic structural damage is as yet unclear. 
Imaging studies clearly show that the inflammatory signal 
rapidly decreases after starting glucocorticoids. Treatment 
is still based largely on glucocorticoids monotherapy, but 
the disease-modifying antirheumatic drugs methotrexate, 
lefunomide, azathioprine and a very recently published 
randomised controlled trial (RCT) in 30 patients with 
tocilizumab, an IL6-receptor blocking biological,9 have 
demonstrated varying benefits. The results of the much 
larger international four arm double-blinded RCT with 
tocilizumab and different steroid-tapering regimens 
(GiACTA, NCT01791153) are awaited soon. 
In summary, Lensen et al. highlight a number of 
challenges in extracranial GCA and new developments 
give us hope that it will not take another 70 years to solve 
the areas of uncertainty presented in their discussion. 
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